MX359664B - Tratamiento de cáncer de mama. - Google Patents

Tratamiento de cáncer de mama.

Info

Publication number
MX359664B
MX359664B MX2014001218A MX2014001218A MX359664B MX 359664 B MX359664 B MX 359664B MX 2014001218 A MX2014001218 A MX 2014001218A MX 2014001218 A MX2014001218 A MX 2014001218A MX 359664 B MX359664 B MX 359664B
Authority
MX
Mexico
Prior art keywords
breast cancer
treatment
compounds
iii
treating
Prior art date
Application number
MX2014001218A
Other languages
English (en)
Other versions
MX2014001218A (es
Inventor
A Protter Andrew
Richer Jennifer
Cochrane Dawn
Original Assignee
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX359664(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Colorado Regents filed Critical Univ Colorado Regents
Publication of MX2014001218A publication Critical patent/MX2014001218A/es
Publication of MX359664B publication Critical patent/MX359664B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición acondicionadora que comprende desde 0.4 a 8% en peso de alcohol graso teniendo desde 8-22 carbonos, desde 0.1 a 2% en peso de componente de surfactante catiónico, agua y en donde la composición tiene una Masa de arrastre desde 1 a 250 g.
MX2014001218A 2011-07-29 2012-07-27 Tratamiento de cáncer de mama. MX359664B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (2)

Publication Number Publication Date
MX2014001218A MX2014001218A (es) 2014-08-22
MX359664B true MX359664B (es) 2018-10-05

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001218A MX359664B (es) 2011-07-29 2012-07-27 Tratamiento de cáncer de mama.

Country Status (18)

Country Link
US (4) US9517229B2 (es)
EP (4) EP3430907A1 (es)
JP (2) JP6158180B2 (es)
KR (1) KR101923250B1 (es)
CN (1) CN103997894B (es)
BR (1) BR112014002200A2 (es)
CA (1) CA2843417C (es)
CY (1) CY1121038T1 (es)
DK (1) DK2739153T3 (es)
EA (1) EA028452B1 (es)
ES (1) ES2696074T3 (es)
HU (1) HUE040524T2 (es)
MX (1) MX359664B (es)
PH (1) PH12014500248B1 (es)
PL (1) PL2739153T3 (es)
PT (1) PT2739153T (es)
SI (1) SI2739153T1 (es)
WO (1) WO2013066440A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2739153T3 (en) * 2011-07-29 2018-12-03 Medivation Prostate Therapeutics Llc TREATMENT OF BREAST CANCER
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
CA3105575A1 (en) * 2013-01-15 2014-07-24 Aragon Pharmaceuticals, Inc. Androgen receptor modulator and uses thereof
BR112015026257B1 (pt) * 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
CA2929715A1 (en) * 2013-11-07 2015-05-14 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie2 kinase useful in the treatment of cancer
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
SG11201704425TA (en) 2014-12-12 2017-06-29 Medivation Prostate Therapeutics Inc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
CN107530291A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 双重负载的脂质体药物制剂
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
UA129105C2 (uk) 2017-10-16 2025-01-15 Арагон Фармасьютикалз, Інк. Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
EA202091763A1 (ru) 2018-01-31 2020-12-14 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Комбинированная терапия для лечения мастоцитоза
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
JP7818502B2 (ja) 2019-08-12 2026-02-20 デシフェラ・ファーマシューティカルズ，エルエルシー 胃腸間質腫瘍を治療するためのリプレチニブ
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
AU2020417282B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
SI4084778T1 (sl) 2019-12-30 2024-01-31 Deciphera Pharmaceuticals, Llc Formulacije inhibitorja amorfne kinaze in načini njihove uporabe
WO2022031630A1 (en) * 2020-08-03 2022-02-10 Oncocyte Corporation Classifying tumors and predicting responsiveness
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP3106162A1 (en) 2005-05-13 2016-12-21 The Regents of the University of California Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US20090299640A1 (en) 2005-11-23 2009-12-03 University Of Utah Research Foundation Methods and Compositions Involving Intrinsic Genes
EP2656842B1 (en) 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
WO2007127010A2 (en) * 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
CA2966280A1 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
US20110130296A1 (en) * 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
AU2009262894B2 (en) 2008-05-30 2014-01-30 British Columbia Cancer Agency Branch Gene expression profiles to predict breast cancer outcomes
MX2011008858A (es) 2009-02-24 2012-01-27 Medivation Prostate Therapeutics Inc Compuestos de diarilhidantoina y diariltiohidantoina especificos.
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
US8507195B2 (en) * 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
EP2485804A4 (en) 2009-10-07 2015-07-29 Medivation Technologies Inc SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
CA2830240A1 (en) 2011-03-15 2012-09-20 The University Of North Carolina At Chapell Hill Methods of treating breast cancer with anthracycline therapy
DK2739153T3 (en) * 2011-07-29 2018-12-03 Medivation Prostate Therapeutics Llc TREATMENT OF BREAST CANCER
CA2857505A1 (en) 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
WO2014031164A1 (en) 2012-08-23 2014-02-27 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US20140154681A1 (en) 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
SG11201704425TA (en) 2014-12-12 2017-06-29 Medivation Prostate Therapeutics Inc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

Also Published As

Publication number Publication date
US20170087132A1 (en) 2017-03-30
ES2696074T3 (es) 2019-01-14
CN103997894A (zh) 2014-08-20
HUE040524T2 (hu) 2019-03-28
JP6158180B2 (ja) 2017-07-05
EA201400178A1 (ru) 2014-11-28
EP3791724A1 (en) 2021-03-17
EP2739153A4 (en) 2015-03-11
PH12014500248A1 (en) 2014-03-17
PT2739153T (pt) 2018-11-28
US20140296312A1 (en) 2014-10-02
SI2739153T1 (sl) 2018-12-31
MX2014001218A (es) 2014-08-22
CN103997894B (zh) 2016-08-24
PL2739153T3 (pl) 2019-04-30
EP2739153A1 (en) 2014-06-11
CA2843417A1 (en) 2013-05-10
CA2843417C (en) 2018-08-21
KR101923250B1 (ko) 2018-11-28
EA028452B1 (ru) 2017-11-30
HK1201413A1 (en) 2015-09-04
US9517229B2 (en) 2016-12-13
US20190262315A1 (en) 2019-08-29
US10111861B2 (en) 2018-10-30
DK2739153T3 (en) 2018-12-03
CY1121038T1 (el) 2019-12-11
PH12014500248B1 (en) 2018-08-31
US20210069154A1 (en) 2021-03-11
JP2014524934A (ja) 2014-09-25
EP2739153B1 (en) 2018-08-22
WO2013066440A9 (en) 2013-07-18
EP3430907A1 (en) 2019-01-23
WO2013066440A1 (en) 2013-05-10
EP3610731A1 (en) 2020-02-19
JP2017141269A (ja) 2017-08-17
BR112014002200A2 (pt) 2017-03-07
HK1198867A1 (en) 2015-06-19
KR20140107174A (ko) 2014-09-04

Similar Documents

Publication Publication Date Title
PH12014500248B1 (en) Treatment of breast cancer
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MA40076A (fr) Inhibiteurs de syk
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
IN2015DN03795A (es)
NZ723971A (en) Methods and compositions for treating ewings sarcoma family of tumors
DOP2015000083A (es) Modulación de la expresión de receptores androgénicos
IN2015DN00438A (es)
MX2013008212A (es) Derivados de 7-azaindol.
EA201390756A1 (ru) Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний
MX2014008864A (es) Derivados de triazolo[4,5-d]pirimidina.
MX2013007268A (es) Activadores de pkm2 bicíclicos.
MX2014014832A (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa.
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
MX2014010713A (es) Activacion de procaspasa 3 mediante terapia de combinacion.
PH12015501088A1 (en) Dimeric compounds
SG10201902568YA (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX2015001551A (es) Compuestos y composiciones activadoras de enzima.
IN2014MN01944A (es)
SG10201900564WA (en) Methods for treating cancer
WO2014110163A3 (en) Melk regulation for the treatment of breast cancer
MX2016008042A (es) Derivados de imidazopirazinona.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ARESCO TECHNOLOGIES, LLC

FG Grant or registration